Edimer Pharmaceuticals, Inc. is a US-based biotechnology company in Cambridge, Massachusetts. Edimer is dedicated to improving the lives of future generations living with X-linked hypohidrotic ectodermal dysplasia (XLHED).
In June 2012, Edimer Pharmaceuticals received fast-track designation from the US Food and Drug Administration (FDA) for EDI200, the company's novel and innovative treatment for XLHED. EDI200 is the first of a new class of drugs designed to treat XLHED with a lifelong effect by correcting the genetic defect responsible for XLHED. If you are interested in learning more about Edimer's clinical trials, please visit www.clinicaltrials.gov.
For further information on Edimer Pharmaceuticals or EDI200, visit www.edimerpharma.com. To receive updates about Edimer Pharmaceuticals' progress in developing a treatment for XLHED, please join the XLHED Network. You'll stay informed on local events and important news.
55 Cambridge Parkway, Suite 102W
Cambridge, MA 02142
Tel: +1 617-758-4300
Fax: +1 866-334-4240